The International Liver Congress™

Beating Liver Disease together

23–26 June 2021

Accepted Abstracts of the Second Round

#ILC2021
Abstract n°213
Category: Liver transplantation and hepatobiliary surgery: Clinical aspects
Title: Immunological risk stratification of stable long-term liver transplant recipients employing non-invasive tools
Presenter: Julien Vionnet

Abstract n°677
Category: Liver tumours: Experimental and pathophysiology
Title: New mouse model of cholangiocarcinoma arising in the setting of progressive biliary injury and fibrosis
Presenter: Pinzhu Huang

Abstract n°737
Category: Rare liver diseases (including paediatric and genetic)
Title: Genetic haemochromatosis, a common disorder but are General Practitioners still unaware? A qualitative study
Presenter: Gerri Mortimore

Abstract n°1578
Category: Immune-mediated and cholestatic: Experimental and pathophysiology
Title: Should normal liver blood tests be the treatment target in primary biliary cholangitis?
Presenter: David Jones

Abstract n°1674
Category: Late breaker
Title: IMbrave150: exploratory efficacy and safety results of atezolizumab + bevacizumab vs sorafenib in patients with unresectable hepatocellular carcinoma (HCC) who had prior locoregional therapy (LRT)
Presenter: Riad Salem

Abstract n°2474
Category: Viral Hepatitis A, B, C, D, E: Virology
Title: Novel HBV cure strategy: Leveraging HBV pol for infected cell-specific killing - In vivo proof-of-concept
Presenter: Serhat Gumrukcu
Abstract n°2476
Category: Non-invasive assessment of liver disease except NAFLD
Title: Development and multicenter external validation of FIB-6; a novel, machine-learning, simple bedside score to rule out severe liver fibrosis and cirrhosis in patients with chronic hepatitis C
Presenter: Gamal Shiha

Abstract n°2478
Category: Viral hepatitis B/D: therapy
Title: VRON-0200, A therapeutic HBV vaccine with an intrinsic checkpoint inhibitor elicits broad CD8+ T cell responses and sustained antiviral declines in preclinical studies
Presenter: Hildegund Ertl

Abstract n°2482
Category: Viral Hepatitis A, B, C, D, E: Virology
Title: Decrease of intrahepatic cccDNA and HBV integration in chronic hepatitis B patients with functional cure
Presenter: Weiqiang Gan

Abstract n°2483
Category: Public Health
Title: The impact of universal hepatitis B vaccine on the trend of hepatitis B virus attributable liver cancer from Global Burden of Disease Study 2017
Presenter: Wen-Qiang He

Abstract n°2484
Category: Viral hepatitis B/D: Clinical aspects except therapy
Title: Nomogram for predicting significant liver injury in chronic hepatitis B patients with immune tolerance
Presenter: Dong Ji

Abstract n°2485
Category: NAFLD: Diagnostics and non-invasive assessment
Title: Assessment of imaging modalities against liver biopsy in non-alcoholic fatty liver disease: the Amsterdam NAFL-NASH cohort
Presenter: Julia Witjes
Abstract n°2524
Category: Cirrhosis and its complications (3): Other clinical complications except ACLF and critical illness
Title: Quality of life improvement is a top-rated but rarely assessed outcome in European and Australian patients with hepatic encephalopathy: Quality of life targeting and monitoring needs to be prioritised
Presenter: Juha Halonen

Abstract n°2529
Category: Cirrhosis and its complications (1): Portal Hypertension
Title: Effects and safety of atrial natriuretic peptide administered to cirrhosis patients with ascites: a systematic review and meta-analysis
Presenter: Rasmus Hvidbjerg Gantzel

Abstract n°2531
Category: Imaging and drug targeting
Title: Fluid dynamics analyses of the portal vein flow changes after hepatectomy using 7T 3D PC-MRI
Presenter: Yu Oshima

Abstract n°2547
Category: Cirrhosis and its complications (2): ACLF and Critical illness
Title: CLIF-SOFA accurately predicts in-hospital mortality in patients with cirrhosis and bacterial infection
Presenter: Minjong Lee

Abstract n°2563
Category: Late breaker
Title: Reduction in Fibrosis and Steatohepatitis Imaging and Biomarkers in a Phase 3 52 Week Resmetirom NASH Trial
Presenter: Stephen Harrison

Abstract n°2572
Category: Cirrhosis and its complications (1): Portal Hypertension
Title: Achieving an effective pressure reduction after TIPS for cirrhotic patients with variceal bleeding
Presenter: xiaoze wang
Abstract n°2575
Category: Viral hepatitis B/D: Clinical aspects except therapy
Title: Restoration of HBV-specific immune responses with therapeutic vaccine BRII-179 (VBI-2601) in chronic HBV patients in a phase 1b/2a study
Presenter: Man-Fung Yuen

Abstract n°2580
Category: Late breaker
Title: ARO-HSD reduces hepatic HSD17B13 mRNA expression and protein levels in patients with suspected NASH
Presenter: Edward Gane

Abstract n°2583
Category: NAFLD: Clinical aspects except therapy
Title: Indirect healthcare costs in biopsy-proven NAFLD is higher than in matched controls and independent of comorbidities
Presenter: Hannes Hagström

Abstract n°2586
Category: Public Health
Title: Uptake of Direct Acting Antivirals for treatment of hepatitis C in human immunodeficiency virus/ hepatitis C co-infected children and adolescents in the Russian Federation
Presenter: Fariyah Malik

Abstract n°2590
Category: Late breaker
Title: Trientine tetrahydrochloride for the treatment of patients with Wilson Disease
Presenter: Karl Heinz Weiss

Abstract n°2592
Category: Late breaker
Title: ARO-AAT an investigational RNAi therapeutic demonstrates improvement in liver fibrosis with reduction in intra-hepatic Z-AAT burden
Presenter: Pavel Strnad
Abstract n°2594
Category: Liver tumours: Clinical aspects except therapy
Title: Free Androgen Index Levels May Influence the Transarterial Chemoembolization with Doxorubicin-Eluting Beads Response in Hepatocellular Carcinoma Patients: Preliminary Results.
Presenter: Silvia Acosta-López

Abstract n°2596
Category: Public Health
Title: Hepatitis C Virus Microelimination is Feasible During COVID-19 Pandemic in Centers for Addiction Treatment Users
Presenter: Silvia Acosta-López

Abstract n°2601
Category: Liver tumours: Experimental and pathophysiology
Title: TIGIT+TIM-3+NK cells are correlated with NK cell exhaustion and disease progression in patients with hepatitis B virus-related hepatocellular carcinoma
Presenter: Lihua Yu

Abstract n°2608
Category: Cirrhosis and its complications (3): Other clinical complications except ACLF and critical illness
Title: Cost-Effectiveness of Rifaximin/alpha versus Lactulose in preventing recurrent episodes of overt hepatic encephalopathy: a systematic review and meta-analysis
Presenter: Kashif Siddiqui

Abstract n°2609
Category: Cirrhosis and its complications (2): ACLF and Critical illness
Title: Geographic variability in rates of intensive care unit admission in patients with chronic liver disease and critical COVID-19: international registry data
Presenter: Thomas Marjot

Abstract n°2612
Category: Liver tumours: Clinical aspects except therapy
Title: Prior or current hepatocellular carcinoma does not adversely affect the evolution of LI-RADS 4 lesions.
Presenter: Louise Hanly
Abstract n°2619
Category: Viral hepatitis B/D: therapy
Title: Effects of tenofovir alafenamide fumarate treatment in pregnant women on maternal viral load reduction and preventing mother-to-infant HBV transmission
Presenter: Huey-Ling Chen

Abstract n°2621
Category: Cirrhosis and its complications (1): Portal Hypertension
Title: Fixed 8-mm diameter VCX stents do not provide clinical advantages compared to former underdilated VTS stents in cirrhotic patients treated with TIPS for refractory ascites
Presenter: Sohaib Mansour

Abstract n°2623
Category: NAFLD: Experimental and pathophysiology
Title: Myeloid-specific fatty acid transport protein 4 deficiency in mice induces a shift towards M2 macrophages that leads to aggravation of NASH after high-fat/high-cholesterol feeding
Presenter: Deniz Göcebe

Abstract n°2627
Category: Molecular and cellular biology
Title: Hepatocytes Caspase6 inhibition exacerbated inflammation and fibrosis in 3D liver spheroids, stellate cells, and the GAN mouse model of NASH
Presenter: Hani Jouihan

Abstract n°2628
Category: Rare liver diseases (including paediatric and genetic)
Title: Novel Copper Protein Speciation method for calculating Serum Non Ceruloplasmin Copper: A comparative analysis
Presenter: Timothy Morley

Abstract n°2631
Category: Late breaker
Title: Combination of amoxicillin/clavulanate and prednisolone in severe alcoholic hepatitis: results of the randomized controlled trial Antibiocor
Presenter: Alexandre Louvet
Abstract n°2634
Category: Cirrhosis and its complications (3): Other clinical complications except ACLF and critical illness
Title: Real-world use of avatrombopag in patients with severe thrombocytopenia associated with chronic liver disease undergoing a procedure
Presenter: Sanjaya Satapathy

Abstract n°2637
Category: Viral hepatitis B/D: Clinical aspects except therapy
Title: In HBeAg-negative patients within grey zone, serum HBV-RNA levels are higher and more commonly detected, while intrahepatic markers are similar
Presenter: Adriana Palom

Abstract n°2647
Category: Late breaker
Title: Adeno-associated virus vector mediated gene therapy for Crigler Najjar syndrome: preliminary report of safety and efficacy from the CareCN clinical trial
Presenter: Lorenzo D'Antiga

Abstract n°2653
Category: NAFLD: Experimental and pathophysiology
Title: Blocking the CD47-SIRPa axis in nonalcoholic steatohepatitis enhances necroptotic hepatocyte uptake and improves hepatic fibrosis
Presenter: Hongxue Shi

Abstract n°2655
Category: Cirrhosis and its complications (1): Portal Hypertension
Title: Splenic vein flow for noninvasive screening for esophageal varices in advanced liver disease patients
Presenter: Sergii Kozlov

Abstract n°2656
Category: Liver development, physiology and regeneration
Title: Cholangiocyte organoids regenerate human bile ducts
Presenter: Fotis Sampaziotis
Abstract n°2657
Category: Immune-mediated and cholestatic disease: Clinical aspects
Title: Patient perspectives on pruritus in intrahepatic cholestasis of pregnancy: a multinational survey
Presenter: Elaine Chien

Abstract n°2666
Category: Liver tumours: Therapy
Title: Primary non-response affects the prognosis of hepatitis B virus-related Hepatocellular Carcinoma after antiviral therapy
Presenter: Peng Wang

Abstract n°2667
Category: Rare liver diseases (including paediatric and genetic)
Title: Three-fold increased risk for death in Budd-Chiari syndrome compared to matched controls - population-based cohort study
Presenter: Hannes Hagström

Abstract n°2673
Category: NAFLD: Clinical aspects except therapy
Title: Colonic permeability is increased in non-cirrhotic nonalcoholic fatty liver disease
Presenter: Toon De Munck

Abstract n°2679
Category: Liver tumours: Therapy
Title: Hepatic arterial infusion chemotherapy in combination with PD-1 inhibitor as conversion therapy in locally advanced, potentially resectable hepatocellular carcinoma: A phase II study
Presenter: Li Xu

Abstract n°2681
Category: Immune-mediated and cholestatic: Experimental and pathophysiology
Title: Altered DNA methylation characterizes autoimmune hepatitis
Presenter: Kalliopi Zachou
Abstract n°2683
Category: Cirrhosis and its complications (3): Other clinical complications except ACLF and critical illness
Title: Validation of a novel point-of-care test for gut leakage in cirrhosis based on dimeric to monomeric IgA ratio: a pilot cohort study
Presenter: Jessica Howell

Abstract n°2684
Category: Viral Hepatitis A, B, C, D, E: Virology
Title: MITOCHONDRIAL STRESS IN PATIENTS WITH CHRONIC HEPATITIS B AND ADVANCED FIBROSIS
Presenter: Dimitri Loureiro

Abstract n°2685
Category: Cirrhosis and its complications (1): Portal Hypertension
Title: Using dimeric to monomeric IgA ratio to diagnose portal hypertension in liver disease: a pilot cohort study
Presenter: Jessica Howell

Abstract n°2686
Category: Liver tumours: Clinical aspects except therapy
Title: International multicenter validation of GES score for HCC risk stratification in CHC patients
Presenter: Gamal Shiha

Abstract n°2687
Category: Liver tumours: Clinical aspects except therapy
Title: SARS-CoV-2 one year on - the worrying impact on early detection of primary liver cancers
Presenter: Daniel Geh

Abstract n°2688
Category: Cirrhosis and its complications (3): Other clinical complications except ACLF and critical illness
Title: Safety and immunogenicity of Coronavirus disease 2019 vaccination in patients with chronic liver disease: a multicenter study
Presenter: Xiaolong Qi
Abstract n°2689
Category: Public Health
Title: Proportion, characteristics, and outcome of chronic hepatitis B who are ‘linked to care’ in Korea: A nationwide retrospective longitudinal study
Presenter: Eileen Yoon

Abstract n°2692
Category: NAFLD: Clinical aspects except therapy
Title: High rate of biopsy-proven advanced fibrosis/cirrhosis among type 2 diabetes patients screened for NAFLD in diabetology clinics (the QUID-NASH project)
Presenter: Laurent Castera

Abstract n°2694
Category: Liver tumours: Experimental and pathophysiology
Title: IncRNA HOTAIR regulates cancer glucose metabolism in hepatocellular carcinoma via the miR-122/PKM2 pathway
Presenter: jiajia zhou

Abstract n°2695
Category: Fibrosis
Title: FIB-4 based algorithm for screening significant fibrosis in diabetes with or without fatty liver in primary care setting
Presenter: Eileen Yoon

Abstract n°2697
Category: Rare liver diseases (including paediatric and genetic)
Title: Defining the range of healthy volunteer non ceruloplasmin copper using a new Copper Protein Speciation assay
Presenter: Timothy Morley

Abstract n°2701
Category: Immune-mediated and cholestatic disease: Clinical aspects
Presenter: Miguel Mascarenhas
Abstract n°2704
Category: Alcoholic liver disease
Title: The Alcohol-Associated Liver Disease Paradox in Chile: An Assessment with data from the National Health Survey 2016-2017.
Presenter: Juan Pablo Roblero

Abstract n°2708
Category: Viral Hepatitis C: Post SVR and long term follow up
Title: Impact of direct-acting antiviral treatment on mortality related to extrahepatic manifestations: findings from a large population-based cohort in British Columbia, Canada
Presenter: Dahn Jeong

Abstract n°2710
Category: NAFLD: Diagnostics and non-invasive assessment
Title: Gamma-Glutamyl Transpeptidase Dynamics as a Biomarker for Advanced Fibrosis in Non-Alcoholic Fatty Liver Disease
Presenter: Yeonjung Ha

Abstract n°2712
Category: Liver tumours: Therapy
Title: Real-world experience of atezolizumab/bevacizumab in hepatocellular carcinoma
Presenter: Yeonjung Ha

Abstract n°2717
Category: Late breaker
Title: Safety and efficacy of bulevirtide monotherapy and in combination with Peginterferon alfa-2a in patients with chronic hepatitis delta: 24 weeks interim data of MYR204 Phase 2b study
Presenter: Tarik Asselah

Abstract n°2719
Category: Immune-mediated and cholestatic disease: Clinical aspects
Title: Cholangiopathy associated with checkpoint inhibitors: a case series
Presenter: Philip Berry
Abstract n°2724
Category: Immune-mediated and cholestatic disease: Clinical aspects
Title: Budesonide versus prednisolone in the treatment of autoimmune hepatitis: a cross-sectional patients' survey
Presenter: Ceyhun Oztumer

Abstract n°2730
Category: Late breaker
Title: Bulevirtide monotherapy at low and high dose in patients with chronic hepatitis delta: 24 weeks interim data of the phase 3 MYR301 study
Presenter: Heiner Wedemeyer

Abstract n°2732
Category: NAFLD: Experimental and pathophysiology
Title: Core liver homeostatic networks: implications in therapeutic target discovery, pre-clinical studies, and innovative trial designs
Presenter: Saeed Esmaili

Abstract n°2735
Category: Viral hepatitis B/D: therapy
Title: Durability of hepatitis B surface antigen seroclearance induced by peginterferon alpha-based regimens
Presenter: Rui Lu

Abstract n°2738
Category: Viral hepatitis B/D: therapy
Title: Functional cure based on pegylated interferon α in long-term nucleoside analog suppressed HBeAg negative chronic hepatitis B: A multicenter real-world study(everest project in china), a sequential report the predictors for HBsAg loss
Presenter: Ze-Qian Wu

Abstract n°2739
Category: NAFLD: Diagnostics and non-invasive assessment
Title: In type-2 diabetic patients, the identification of at-risk NASH is impacted by age: a comparison of serum-based NITs including NIS4
Presenter: Vlad Ratziu
Abstract n°2742
Category: Liver tumours: Experimental and pathophysiology
Title: Preoperative artemin as predictive biomarker for survival in curatively resected hepatocellular carcinoma
Presenter: Ulf Zeuge

Abstract n°2749
Category: Alcoholic liver disease
Title: The combination of ABIC+ELF as a single marker outperforms ABIC alone in predicting 90-day survival in alcoholic hepatitis.
Presenter: Freya Rhodes

Abstract n°2750
Category: Late breaker
Title: Estimating the contribution of viral hepatitis and other etiologies to the burden of cirrhosis: a worldwide systematic review
Presenter: Catharina Alberts

Abstract n°2753
Category: Cirrhosis and its complications (3): Other clinical complications except ACLF and critical illness
Title: Supplementation of branched-chain amino acids improves event-free survival in cirrhotic patients: systematic review and meta-analysis
Presenter: Karel J. van Erpecum

Abstract n°2754
Category: Fibrosis
Title: Liver progenitor cells regulate ductular reaction and induce fibrosis upon severe liver injury via RAGE signaling
Presenter: Wai Ling Macrina Lam

Abstract n°2755
Category: Liver tumours: Clinical aspects except therapy
Title: A lesson from COVID19: the persevering benefits of hepatocellular carcinoma surveillance
Presenter: William Cunliffe
Abstract n°2759
Category: Viral hepatitis B/D: therapy
Title: Short-term peginterferon alpha re-treatment induced a high functional cure rate in patients with hepatitis B surface antigen recurrence after cessation of peginterferon alpha-based regimens
Presenter: Feng-ping Wu

Abstract n°2761
Category: Immune-mediated and cholestatic disease: Clinical aspects
Title: Ischemic cholangiopathy in biliary atresia: immunohistochemical and molecular evidence
Presenter: Jorge Luiz dos Santos

Abstract n°2764
Category: Late breaker
Title: Repeat dosing of the GalNAc-siRNA AB-729 in subjects with chronic hepatitis B results in robust and sustained HBsAg suppression
Presenter: Man-Fung Yuen

Abstract n°2765
Category: Cirrhosis and its complications (3): Other clinical complications except ACLF and critical illness
Title: Treatment of iron deficiency anemia with intravenous ferric carboxymaltose improves significantly systemic hemodynamics, renal function, and survival in patients with cirrhosis and ascites
Presenter: Ilias Tsiakas

Abstract n°2770
Category: Rare liver diseases (including paediatric and genetic)
Title: Optimization of CRISPR/Cas9 technology for a safer treatment of rare metabolic disorders
Presenter: Laura Torella

Abstract n°2779
Category: Cirrhosis and its complications (2): ACLF and Critical illness
Title: Targeted albumin therapy increases serum sodium in hospitalized cirrhosis patients with hyponatremia at baseline, but has no effect on short term outcome; a sub study from the ATTIRE Trial
Presenter: Alastair O'Brien
Abstract n°2782
Category: Immune-mediated and cholestatic disease: Clinical aspects
Title: Bacterial and fungal colonisation of bile ducts associates with the prognosis of Primary Sclerosing Cholangitis
Presenter: Ehud Zigmond

Abstract n°2786
Category: Liver tumours: Clinical aspects except therapy
Title: Insulin like growth factor-1 as a prognostic tool for overall survival in chronic hepatitis C cirrhotic Egyptian patients with hepatocellular carcinoma
Presenter: Ahmed Sultan

Abstract n°2787
Category: Liver tumours: Experimental and pathophysiology
Title: Identifying effective subtype-specific treatment responses in hepatocellular carcinoma in genetically engineered mouse models
Presenter: Miryam Müller

Abstract n°2788
Category: Cirrhosis and its complications (1): Portal Hypertension
Title: Umbilical hernia repair in Cirrhosis: TIPS insertion improves one-year survival but not long-term outcomes
Presenter: Abdullah Malik

Abstract n°2790
Category: Fibrosis
Title: Liver fibrosis accumulation depends on underlying disease aetiology
Presenter: Adam Watson

Abstract n°2791
Category: NAFLD: Clinical aspects except therapy
Title: Liver test-derived R factor is associated with portal hypertension in patients with non-alcoholic fatty liver disease
Presenter: Dor Shirin
Abstract n°2792
Category: Late breaker
Title: HLA-A mismatching is associated with an increased risk of hepatic artery thrombosis, sepsis, graft loss and reduced survival following liver transplant
Presenter: Christopher Bricogne

Abstract n°2793
Category: Molecular and cellular biology
Title: Disrupted glucose-6-phosphate-ChREBP signalling aggravates hepatomegaly and accelerates liver disease progression in a mouse model for Glycogen Storage Disease type 1a
Presenter: Martijn Rutten

Abstract n°2798
Category: Liver tumours: Experimental and pathophysiology
Title: Phosphoinositide 3-kinase dependent carcinogenesis in the liver
Presenter: Dayana Tsolova

Abstract n°2799
Category: Liver tumours: Clinical aspects except therapy
Title: Early SARS-CoV-2-related mortality of liver cancer patients: Cancer stage matters.
Presenter: Sergio Munoz-Martinez

Abstract n°2800
Category: Late breaker
Title: Efruxifermin (EFX) improved markers of fibrosis, liver injury and metabolism in F4 NASH patients with compensated cirrhosis
Presenter: Stephen Harrison

Abstract n°2801
Category: Immune-mediated and cholestatic disease: Clinical aspects
Title: Artificial Intelligence for automatic diagnosis of biliary strictures malignancy status in Single-Operator Cholangioscopy.
Presenter: Miguel Mascarenhas
Abstract n°2812
Category: Liver tumours: Clinical aspects except therapy
Title: Trend and correlates of increased serum alpha-fetoprotein in hepatocellular carcinoma: US National Cancer Database analysis
Presenter: Aarshi Vipani

Abstract n°2814
Category: Late breaker
Title: Modeling HCV elimination recovery following the COVID-19 pandemic in the United States: Pathways to regain progress
Presenter: Sarah Blach

Abstract n°2821
Category: Liver transplantation and hepatobiliary surgery: Clinical aspects
Title: SARS-CoV-2-specific cellular and humoral immunity in COVID-19 convalescence after liver transplantation
Presenter: Theresa Kirchner

Abstract n°2822
Category: Viral hepatitis B/D: therapy
Title: Inhibition of hepatitis B surface antigen by RNA interference therapeutic AB-729 in chronic hepatitis B patients correlates with suppression of all HBsAg isoforms and HBV RNA
Presenter: Emily P. Thi

Abstract n°2823
Category: Viral hepatitis B/D: therapy
Title: Inhibition of hepatitis B surface antigen in chronic hepatitis B subjects by RNA interference hepatitis B therapeutic AB-729 is accompanied by upregulation of HBV-specific T cell activation markers
Presenter: Emily P. Thi

Abstract n°2826
Category: Late breaker
Title: Profiling anti-HBs; immune complex peaks, epitope occupancy, ADCC phenotype and neutralization profiles associated with functional cure in a genotype A chronic hepatitis B cohort.
Presenter: Nadia Warner
Abstract n°2828
Category: Liver tumours: Experimental and pathophysiology
Title: Characterization of disease progression and pharmacological intervention in a diet-induced obese mouse model of NASH with advanced fibrosis and hepatocellular carcinoma
Presenter: Michael Feigh

Abstract n°2830
Category: Immune-mediated and cholestatic disease: Clinical aspects
Title: A novel histological scoring system for primary sclerosing cholangitis: Impact on disease outcome
Presenter: Nelli Sjöblom

Abstract n°2831
Category: NAFLD: Experimental and pathophysiology
Title: Pro-inflammatory hepatic progenitor cell response is associated with progression of human non-alcoholic fatty liver disease
Presenter: Olivier Govaere

Abstract n°2832
Category: Cirrhosis and its complications (3): Other clinical complications except ACLF and critical illness
Title: High prevalence of hormonal changes and hepatic osteodystrophy in Frail patients with cirrhosis An observational study
Presenter: Surender Singh

Abstract n°2833
Category: Cirrhosis and its complications (4): Experimental and pathophysiology
Title: Early and late changes in the phenotype of liver sinusoidal endothelial cells (LSECs) along the development of heart failure
Presenter: Kamila Wojnar-Lasoń

Abstract n°2834
Category: Viral hepatitis B/D: Clinical aspects except therapy
Title: HBsAg protein composition differs across stages of hepatitis B and hepatitis Delta: a validation cohort study
Presenter: Luisa Roade
Abstract n°2836
Category: Viral Hepatitis C: Post SVR and long term follow up
Title: Higher all-cause mortality in individuals living with HIV cured of HCV by direct-acting antivirals compared to HIV mono-infection despite controlled HIV: Results from the ANRS-CO4 FHDH cohort
Presenter: Maria Requena

Abstract n°2839
Category: Liver tumours: Experimental and pathophysiology
Title: Tumor progression in intrahepatic cholangiocarcinoma
Presenter: Sophie Pirenne

Abstract n°2842
Category: Liver transplantation and hepatobiliary surgery: Clinical aspects
Title: Periods of high or low intensity transplant activity are not associated with changes in liver transplant outcomes
Presenter: Neil Halliday

Abstract n°2844
Category: Viral hepatitis B/D: therapy
Title: A phase 2 study testing FXR agonist Vonafexor in treatment naive patients with chronic hepatitis B (CHB): preliminary week 16 results
Presenter: Pietro Scalfaro

Abstract n°2851
Category: Cirrhosis and its complications (4): Experimental and pathophysiology
Title: In vitro skeletal muscle cell atrophy and mitochondrial dysfunction after exposure to human serum from patients with ESLD and NAFLD
Presenter: Sophie Allen

Abstract n°2853
Category: Viral hepatitis B/D: therapy
Title: The incidence of hepatocellular carcinoma in patients with hepatitis B cirrhosis during long-term antiviral therapy: A real world cohort study
Presenter: Ying Han
Abstract n°2854
Category: Late breaker
Title: Elderly with advanced liver fibrosis had lower response to Pfizer’s SARS-CoV-2 vaccine response
Presenter: David Hakimian

Abstract n°2858
Category: NAFLD: Experimental and pathophysiology
Title: Role of the nuclear receptor Farnesoid X Receptor in the immune functions of the intestine in the pathophysiological context of Non Alcoholic SteatoHepatitis
Presenter: Margaux Nawrot

Abstract n°2861
Category: Public Health
Title: Projecting the prevalence of obesity- and alcohol- related non-communicable diseases in France, the Netherlands and Romania from 2020 to 2030 using multi-risk microsimulation methods
Presenter: Lise Retat

Abstract n°2864
Category: Viral Hepatitis A, B, C, D, E: Virology
Title: Quantification of viral RNA in multiple pieces of liver tissue shows distinct focal differences of hepatitis B infection
Presenter: Gustaf Rydell

Abstract n°2865
Category: Liver tumours: Experimental and pathophysiology
Title: Proteomic profiling of hepatocellular adenomas paves the way to new diagnostic and prognostic approaches
Presenter: Anne-Aurélie Raymond

Abstract n°2867
Category: Cirrhosis and its complications (3): Other clinical complications except ACLF and critical illness
Title: Hepatogenous diabetes in patients with cirrhosis and ascites: correlation with inflammatory activity, systemic hemodynamics, renal function, and outcome
Presenter: Ilias Tsiakas
Abstract n°2870
Category: Cirrhosis and its complications (2): ACLF and Critical illness
Title: Methylation state of circulating cell-free DNA as a prognostic marker for early to late stage chronic liver disease and acute on chronic liver failure
Presenter: Vishal C Patel

Abstract n°2872
Category: Public Health
Title: COVID-19 pandemic and the impact on hospitalization of alcohol related liver disease - A retrospective cohort study in a secondary care setting
Presenter: Wei Jin Lim

Abstract n°2879
Category: Viral hepatitis B/D: therapy
Title: A single dose of the GalNAc-siRNA, AB-729, results in prolonged reductions in HBsAg, HBcrAg, HBV DNA and HBV RNA in the absence of nucleos(t)ide analogue therapy in HBeAg negative subjects with chronic hepatitis B infection
Presenter: Edward Gane

Abstract n°2883
Category: NAFLD: Experimental and pathophysiology
Title: The intestinal barrier is modified in mice suffering from non-alcoholic steatohepatitis
Presenter: Simon Peschard

Abstract n°2886
Category: Late breaker
Title: LPCN 1144 improves body composition in biopsy-confirmed NASH patients
Presenter: Shadi Mehraban

Abstract n°2887
Category: Immune-mediated and cholestatic disease: Clinical aspects
Title: Artificial intelligence and digital single-operator cholangioscopy: automatic identification of neoplastic biliary nodules in patients with indeterminate biliary stenosis.
Presenter: João Afonso
Abstract n°2888
Category: Acute liver failure and drug induced liver injury
Title: New insights in CCl4 induced acute liver injury in the presence and absence of Ripk1.
Presenter: Huma Hameed

Abstract n°2890
Category: Liver transplantation and hepatobiliary surgery: Clinical aspects
Title: A new tool for predicting survival in liver transplantation for hepatocellular carcinoma combining molecular and clinical variables
Presenter: Hugo Pinto Marques

Abstract n°2891
Category: Late breaker
Title: Artificial intelligence and digital single-operator cholangioscopy: automatic identification of papillary projections in patients with indeterminate biliary strictures
Presenter: Tiago Ribeiro

Abstract n°2893
Category: Liver tumours: Clinical aspects except therapy
Title: Micro ribonucleic acid-26a as a diagnostic biomarker for hepatitis C induced hepatocellular carcinoma in Egyptian patients.
Presenter: Ahmed Sultan

Abstract n°2898
Category: Immune-mediated and cholestatic disease: Clinical aspects
Title: Artificial intelligence and digital single-operator cholangioscopy: automatic identification of neoplastic masses in patients with indeterminate biliary strictures
Presenter: Tiago Ribeiro

Abstract n°2902
Category: Rare liver diseases (including paediatric and genetic)
Title: Impact of SarsCov2 pandemic on vascular liver diseases
Presenter: Anna Baiges
Abstract n°2904
Category: Public Health
Title: Impact of Universal Automated Hepatitis C Screening with Treatment and Cure in a Primary Care Based Practice
Presenter: Ruth Brogden

Abstract n°2907
Category: Late breaker
Title: Icosabutate, a novel structurally engineered fatty acid, significantly reduces relevant markers of NASH and fibrosis in 16 weeks: interim analysis results of the ICONA trial
Presenter: Stephen Harrison

Abstract n°2910
Category: Liver transplantation and hepatobiliary surgery: Clinical aspects
Title: Liver and/or kidney transplantation after SARS-CoV-2 infection: Prevalence, short-term outcome and kinetics of serum IgG antibodies
Presenter: Jef Verbeek

Abstract n°2914
Category: Gut microbiota and liver disease
Title: Fecal microbiota transplantation (FMT) for corticosteroids (CS) non-responders and non-eligible (NoReNE) patients with severe alcoholic hepatitis (SAH).
Presenter: Natalia Bystrianska

Abstract n°2919
Category: Liver tumours: Experimental and pathophysiology
Title: Transcriptomic analysis reveals circWHSC1 and circCPSF6 serves as the oncogene to promote hepatocellular carcinoma progression
Presenter: Fei Lu

Abstract n°2920
Category: Liver tumours: Experimental and pathophysiology
Title: Exploring molecular signatures (circulating tumour cells, microRNAs, proteomics) as possible biomarkers of early hepatocellular carcinoma
Presenter: Athanasios Armakolas
Abstract n°2934
Category: Molecular and cellular biology
Title: Identifying patient relevant tumour suppressors that interact with oncogenic KrasG12D in intrahepatic cholangiocarcinoma
Presenter: Mollie Wilson

Abstract n°2936
Category: Non-invasive assessment of liver disease except NAFLD
Title: Improving the Accuracy of Non-Invasive Tests for Prediction of Cirrhosis in Chronic Hepatitis Delta: Insights from 230 Patients of the D-LIVR Study
Presenter: Tarik Asselah

Abstract n°2938
Category: Cirrhosis and its complications (1): Portal Hypertension
Title: Application of surrogate endpoints in compensated cirrhotic patients with primary biliary cholangitis
Presenter: Carla Fiorella Murillo Perez

Abstract n°2946
Category: Viral Hepatitis C: Post SVR and long term follow up
Title: Patients with cirrhosis show an improvement in dynamic liver function following the eradication of hepatitis C virus with direct acting antivirals
Presenter: Jibran mecci

Abstract n°2951
Category: Cirrhosis and its complications (3): Other clinical complications except ACLF and critical illness
Title: An educational intervention that effectively reduces the inappropriate administration of proton pump inhibitors in patients with cirrhosis
Presenter: Juvelyn Palomique